Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization

Addiction

Volumn 111, Issue 5, 2016, Pages 892-902

  Lo Ciganic, Wei Hsuan ^a,b   Gellad, Walid F ^b,c,d   Gordon, Adam J ^b,c,d   Cochran, Gerald ^b   Zemaitis, Michael A ^b   Cathers, Terri ^e   Kelley, David ^e   Donohue, Julie M ^b,f  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e Pennsylvania Department of Agriculture   (United States)

^f UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Buprenorphine; Group based trajectory models; Medicaid; Opioid agonist therapy; Opioid use disorders; Trajectories; Treatment duration; Treatment patterns

Indexed keywords

BUPRENORPHINE; NARCOTIC ANALGESIC AGENT;

ADOLESCENT; ADULT; FEMALE; HOSPITAL EMERGENCY SERVICE; HOSPITALIZATION; HUMAN; MALE; MEDICAID; MIDDLE AGED; OPIOID-RELATED DISORDERS; PENNSYLVANIA; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; UNITED STATES; UTILIZATION; YOUNG ADULT;

ADOLESCENT; ADULT; ANALGESICS, OPIOID; BUPRENORPHINE; EMERGENCY SERVICE, HOSPITAL; FEMALE; HOSPITALIZATION; HUMANS; MALE; MEDICAID; MIDDLE AGED; OPIOID-RELATED DISORDERS; PENNSYLVANIA; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84958012408     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.13270     Document Type: Article

References (58)

1. Degenhardt L., Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 2012; 379: 55-70.
2. Substance Abuse and Mental Health Services Administration. Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings. NSDUH Series H-48, HHS Publication No. (SMA) 14-4863. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2014.
3. National Institute of Drug Abuse. Prescription Drug Abuse. Available at: http://www.drugabuse.gov/publications/research-reports/prescription-drugs/trends-in-prescription-drug-abuse/how-many-people-suffer-adverse-health-cons (Archived by WebCite® at http://www.webcitation.org/6blQcOzwC) (accessed 23 September 2015).
4. Birnbaum H. G., White A. G., Schiller M., Waldman T., Cleveland J. M., Roland C. L. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med 2011; 12: 657-67.
5. Fudala P. J., Bridge T. P., Herbert S., Williford W. O., Chiang C. N., Jones K. et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003; 349: 949-58.
6. Fiellin D. A., Pantalon M. V., Chawarski M. C., Moore B. A., Sullivan L. E., O'Connor P. G. et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence, N Engl J Med 2006; 355; 365-74.
7. Parran T. V., Adelman C. A., Merkin B., Pagano M. E., Defranco R., Ionescu R. A. et al. Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy. Drug Alcohol Depend 2010; 106: 56-60.
8. Barnett P. G. Comparison of costs and utilization among buprenorphine and methadone patients. Addiction 2009; 104: 982-92.
9. Jones E. S., Moore B. A., Sindelar J. L., O'Connor P. G., Schottenfeld R. S., Fiellin D. A. Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients. Drug Alcohol Depend 2009; 99: 132-40.
10. Mattick R. P., Breen C., Kimber J., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014; 2: CD002207.
11. Volkow N. D., Frieden T. R., Hyde P. S., Cha S. S. Medication-assisted therapies-tackling the opioid-overdose epidemic. N Engl J Med 2014; 370: 2063-6.
12. Fiellin D. A., O'Connor P. G. Clinical practice. Office-based treatment of opioid-dependent patients. N Engl J Med 2002; 347: 817-23.
13. Ducharme L. J., Abraham A. J. State policy influence on the early diffusion of buprenorphine in community treatment programs. Subst Abuse Treat Prev Policy 2008; 3: 17.
14. Rosenblatt R. A., Andrilla C. H., Catlin M., Larson E. H. Geographic and specialty distribution of us physicians trained to treat opioid use disorder. Ann Fam Med 2015;13:23-6.
15. Oliva E. M., Maisel N. C., Gordon A.J., Harris A. H. S. Barriers to use of pharmacotherapy for addiction disorders and how to overcome them. Curr Psychiatry Rep 2011;13:374-81.
16. Gordon A. J., Krumm M. M. Buprenorphine for opioid dependence. In: Miller P. M., editor. Interventions for Addiction: Comprehensive Addictive Behaviors and Disorders. San Diego, CA: Elsevier Inc., Academic Press; 2013; pp. 417-26.
17. Fiellin D. A., Schottenfeld R. S., Cutter C. J., Moore B. A., Barry D. T., O'Connor P. G. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. JAMA Intern Med 2014; 174: 1947-54.
18. Kraus M. L., Alford D. P., Kotz M. M., Levounis P., Mandell T. W., Meyer M. et al. Statement of the American Society of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction. J Addict Med 2011; 5: 254-63.
19. Kleber H. D. Pharmacologic treatments for opioid dependence: detoxification and maintenance options. Dialogues Clin Neurosci 2007; 9: 455-70.
20. Weiss R. D., Potter J. S., Fiellin D. A., Byrne M., Connery H. S., Dickinson W. et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry 2011; 68: 1238-46.
21. Kornor H., Waal H., Sandvik L. Time-limited buprenorphine replacement therapy for opioid dependence: 2-year follow-up outcomes in relation to programme completion and current agonist therapy status. Drug Alcohol Rev 2007; 26: 135-41.
22. Franklin J. M., Shrank W. H., Pakes J., Sanfelix-Gimeno G., Matlin O. S., Brennan T. A. et al. Group-based trajectory models: a new approach to classifying and predicting long-term medication adherence. Med Care 2013; 51: 789-96.
23. Modi A. C., Rausch J. R., Glauser T. A. Patterns of nonadherence to antiepileptic drug therapy in children with newly diagnosed epilepsy. JAMA 2011; 305: 1669-76.
24. Garfield R. L., Lave J. R., Donohue J. M. Health reform and the scope of benefits for mental health and substance use disorder services. Psychiatr Serv 2010; 61: 1081-6.
25. Kaiser Family Foundation. Medicaid & CHIP. Available at: URL:http://kff.org/state-category/medicaid-chip/(Archived by WebCite® at http://www.webcitation.org/6bmvEtvO6) (accessed 24 September 2015).
26. Roberts A. W., Dusetzina S. B., Farley J. F. Revisiting the washout period in the incident user study design: why 6-12 months may not be sufficient. J Comp Eff Res 2015; 4: 27-35.
27. Ho P. M., Rumsfeld J. S., Masoudi F. A., McClure D. L., Plomondon M. E., Steiner J. F. et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006; 166: 1836-41.
28. Sheehan D. V., Keene M. S., Eaddy M., Krulewicz S., Kraus J. E., Carpenter D. J. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders. CNS Drugs 2008; 22: 963-73.
29. Wu P. H., Yang C. Y., Yao Z. L., Lin W. Z., Wu L. W., Chang C. C. Relationship of blood pressure control and hospitalization risk to medication adherence among patients with hypertension in Taiwan. Am J Hypertens 2010; 23: 155-60.
30. Simoni-Wastila L., Wei Y. J., Qian J., Zuckerman I. H., Stuart B., Shaffer T. et al. Association of chronic obstructive pulmonary disease maintenance medication adherence with all-cause hospitalization and spending in a Medicare population., Am J Geriatr Pharmacother 2012; 10: 201-10.
31. Lang K., Federico V., Muser E., Menzin J., Menzin J. Rates and predictors of antipsychotic non-adherence and hospitalization in Medicaid and commercially-insured patients with schizophrenia. J Med Econ 2013; 16: 997-1006.
32. Peterson A. M., Nau D. P., Cramer J. A., Benner J., Gwadry-Sridhar F., Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007; 10: 3-12.
33. Nau D. P. Proportion of Days Covered (PDC) as a Preferred Method of Measuring Medication Adherence: Pharmacy Quality Alliance; 2012. Available at: http://www.pqaalliance.org/images/uploads/files/PQA%20PDC%20vs%20%20MPR.pdf (Archived by WebCite® at http://www.webcitation.org/6bmxdaZBM) (accessed 24 September 2015).
34. Nagin D. S. Group-Based Modeling of Development. Cambridge, MA: Harvard University Press; 2005.
35. Nagin D. S., Odgers C. L. Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol 2010; 6: 109-38.
36. Twisk J., Hoekstra T. Classifying developmental trajectories over time should be done with great caution: a comparison between methods. J Clin Epidemiol 2012; 65: 1078-87.
37. Stein M. D., Cioe P., Friedmann P. D. Buprenorphine retention in primary care. J Gen Intern Med 2005; 20: 1038-41.
38. Stroupe K. T., Teal E. Y., Tu W., Weiner M., Murray M. D. Association of refill adherence and health care use among adults with hypertension in an urban health care system. Pharmacotherapy 2006; 26: 779-89.
39. Stroupe K. T., Murray M. D., Stump T. E., Callahan C. M. Association between medication supplies and healthcare costs in older adults from an urban healthcare system. J Am Geriatr Soc 2000; 48: 760-8.
40. Gordon A. J., Kavanagh G., Krumm M., Ramgopal R., Paidisetty S., Aghevli M. et al. Facilitators and barriers in implementing buprenorphine in the Veterans Health Administration. Psychol Addict Behav 2011; 25: 215-24.
41. Gordon A. J., Haas G. L., Luther J. F., Hilton M. T., Goldstein G. Personal, medical, and healthcare utilization among homeless veterans served by metropolitan and nonmetropolitan veteran facilities. Psychopharmacol Ser 2010; 7: 65-74.
42. Stein B. D., Gordon A. J., Sorbero M., Dick A. W., Schuster J., Farmer C. The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone. Drug Alcohol Depend 2012; 123: 72-8.
43. Oliva E. M., Harris A. H. S., Trafton J. A., Gordon A. J. Receipt of opioid agonist treatment in the Veterans Health Administration: facility and patient factors. Drug Alcohol Depend 2012; 122: 241-6.
44. Miotto K., Hillhouse M., Donovick R., Cunningham-Rathner J., Charuvastra C., Torrington M. et al. Comparison of buprenorphine treatment for opioid dependence in 3 settings. J Addict Med 2012; 6: 68-76.
45. Choudhry N. K., Fischer M. A., Avorn J., Liberman J. N., Schneeweiss S., Pakes J. et al. The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med 2011; 171: 814-22.
46. Elixhauser A., Steiner C., Harris D. R., Coffey R. M. Comorbidity measures for use with administrative data. Med Care 1998; 36: 8-27.
47. Grambsch P. M., Therneau T. M. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994; 81: 515-26.
48. Boothby L. A., Doering P. L. Buprenorphine for the treatment of opioid dependence. Am J Health Syst Pharm 2007; 64: 266-72.
49. Hser Y. I., Saxon A. J., Huang D., Hasson A., Thomas C., Hillhouse M. et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction 2014; 109: 79-87.
50. Gryczynski J., Mitchell S. G., Jaffe J. H., O'Grady K. E., Olsen Y. K., Schwartz R. P. Leaving buprenorphine treatment: patients' reasons for cessation of care. J Subst Abuse Treat 2014; 46: 356-61.
51. Khanna R., Pace P. F., Mahabaleshwarkar R., Basak R. S., Datar M., Banahan B. F. Medication adherence among recipients with chronic diseases enrolled in a state Medicaid program. Popul Health Manag 2012; 15: 253-60.
52. Medical Assistance Handbook-Prior Authorization of Pharmaceutical Services: Requirements for Prior Authorization of Opiate Dependence Treatments. Pennsylvania Department of Public Welfare Medical Assistance; 2014. Available at: http://www.dpw.state.pa.us/cs/groups/webcontent/documents/bulletin_admin/c_084856.pdf (Archived by WebCite® at http://www.webcitation.org/6bn6mRJ0c) (accessed 24 September 2015).
53. Advancing Access to Addiction Medications: Implications for Opioid Addiction Treatment. American Society of Addiction Medicine. 2013. Available at: http://www.asam.org/docs/default-source/advocacy/aaam_implications-for-opioid-addiction-treatment_final (Archived by WebCite® at http://www.webcitation.org/6bn7TTm0n) (accessed 24 September 2015).
54. Clark R. E., Baxter J. D. Responses of state Medicaid programs to buprenorphine diversion: doing more harm than good? JAMA Intern Med 2013; 173: 1571-2.
55. Clark R. E., Baxter J. D., Barton B. A., Aweh G., O'Connell E., Fisher W. H. The impact of prior authorization on buprenorphine dose, relapse rates, and cost for Massachusetts Medicaid beneficiaries with opioid dependence. Health Serv Res 2014; 49: 1964-79.
56. Degenhardt L., Bucello C., Mathers B., Briegleb C., Ali H., Hickman M. et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction 2011; 106: 32-51.
57. Gordon A.J., Lo-Ciganic W., Cochran G., Gellad W.F., Cathers T., Kelley D. et al. Patterns and quality of buprenorphine opioid agonist treatment in a large Medicaid program. J Addict Med. 2015; 9: 470-7.
58. Brookhart M. A., Patrick A. R., Dormuth C., Avorn J., Shrank W., Cadarette S. M. et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol 2007; 166: 348-54.